LIAISON Biotrin Parvovirus B19 IgG Plus; LIAISON Biotrin Control Parvovirus B19 IgG Plus
DiaSorin, Inc. · Decision date Aug 18, 2026
What did the FDA approve?
FDA records P220034/S010 as a supplement to PMA P220034, with the supplement type “Normal 180 Day Track”. The recorded decision is approval, dated Aug 18, 2026.
FDA approval order statement
Approval of the LIAISON diluteX as an accessory to LIAISON XL analyzer for use with the LIAISON Biotrin Parvovirus B19 IgG Plus assay
- Regulatory pathway
- PMA supplement
- Supplement type
- Normal 180 Day Track
- Clinical specialty
- Microbiology
- Decision date
- Aug 18, 2026
- FDA change category
- Labeling Change - Indications/instructions/shelf life/tradename
Regulatory record facts
- Identifier
- P220034/S010
- Regulatory pathway
- PMA supplement
- Applicant
- DiaSorin, Inc.
- Product code
- MYL
- Decision code
- APPR
- Decision date
- Aug 18, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: ASSAY,ENZYME LINKED IMMUNOSORBENT,PARVOVIRUS B19 IGG.
- Applicant
- DiaSorin, Inc.
- Product code
- MYL
- FDA device class
- 3
Review the original FDA PMA listing for the original approval scope and linked supplements.
FDA decision timeline
P220034/S007 · Related supplement
LIAISON Biotrin Parvovirus B19 IgG Plus, LIAISON Biotrin Control Parvovirus B19 IgG Plus
P220034/S008 · Related supplement
LIAISON Biotrin Parvovirus B19 IgG Plus, LIAISON Biotrin Control Parvovirus B19 IgG Plus
P220034/S010 received
Application receipt date recorded by FDA.
P220034/S011 · Related supplement
LIAISON Biotrin Parvovirus B19 IgG Plus, LIAISON Biotrin Control Parvovirus B19 IgG Plus
P220034/S010 · FDA decision
Normal 180 Day Track
Timeline entries are records held by MedtechLedger for P220034. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P220034
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| DiaSorin, Inc. | PMA supplement | Oct 10, 2025 | FDA | |
| DiaSorin, Inc. | PMA supplement | Dec 19, 2025 | FDA | |
| DiaSorin, Inc. | PMA supplement | Jun 24, 2026 | FDA |
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
DiaSorin, Inc.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 1951 Northwestern Ave., Stillwater, MN, 55082
Sources and methodology
- Original FDA record: P220034/S010
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 20, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records
